Anemia in CKD: Pathophysiology and management overview

View at publisher Summarise with VIRAT
Authors: G Tejaswani, M Yasoda, MD Bibi Ameena, Divya Kaveri, SK Usama, S Ashok, JN Suresh Kumar
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Anemia is a common and significant complication in patients with chronic kidney disease (CKD), resulting primarily from reduced erythropoietin production, iron deficiency, and chronic inflammation. Early diagnosis and effective management are crucial to improve quality of life and reduce morbidity. Diagnosis involves a comprehensive evaluation including hemoglobin levels, iron studies (serum ferritin, transferrin saturation), and exclusion of other causes of anemia. Management centers on correcting underlying deficiencies with iron supplementation—oral or intravenous—optimizing erythropoiesis-stimulating agents (ESAs), and addressing contributing factors such as inflammation and nutritional deficiencies. Recent advances emphasize individualized treatment targets to balance benefits and risks, including cardiovascular complications and ESA resistance. Multidisciplinary care is essential for optimal outcomes in CKD-associated anemia.

Fields of Study & Subjects

Erythropoietin and Anemia Treatment Iron Metabolism and Disorders Dialysis and Renal Disease Management

Publication details

Journal / source
International Journal of Pharmacology and Clinical Research
Volume
8
Issue
3
Pages
133–137
Publication date
1 March 2026
Language
EN